Back to company

NUEVOLUTION A/S: Financial statements 2022

CVR: 26029708

NUEVOLUTION A/S (CVR 26029708) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 68,498,000 and a net result of DKK -28,120,000 compared with DKK 62,971,000 the year before. That is a decrease of 57.8% compared with the year before. The profit margin was -41.1%. Equity amounted to DKK 104,330,000. The solvency ratio was 71.8%. The company had 63 employees in the financial year.

Revenue
68,498,000 kr.
Profit/Loss
-28,120,000 kr.
Equity
104,330,000 kr.
Total Assets
145,248,000 kr.
Employees
63

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
202268.5 mio.--28.1 mio.104.3 mio.63
2021162.3 mio.-63 mio.132.4 mio.56
202037 mio.--33.5 mio.69.5 mio.54
201917.4 mio.--76.3 mio.1.8 mio.49
20188.1 mio.--64.3 mio.64.9 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on NUEVOLUTION A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

NUEVOLUTION A/S: The 2021 annual report is outJun 22, 2022

NUEVOLUTION A/S has published its annual report for 2021. Revenue came to DKK 162,279,000, and the net result was DKK 62,971,000.

About NUEVOLUTION A/S

NUEVOLUTION A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CHEMGENE ApS. The management consists of Thomas Franch. The company is owned by Amgen, Inc.. The company has 59 employees. In 2025, the company reported revenue of DKK 203,323,000 and a net result of DKK 39,754,000 compared with DKK -18,383,000 the year before. Equity amounted to DKK 89,493,000.